Carbohydrate Reduction and Impact on Gastrointestinal System (CRAIGS)
1 de novembro de 2018 atualizado por: University of Nottingham
A Pilot Randomised Controlled Trial of the Effect of a Diet Low in Poorly Digested Carbohydrates on Gastrointestinal Form and Symptoms in Irritable Bowel Syndrome Patients
Title :
A pilot single blind randomised controlled trial of the effect of a diet low in poorly digested carbohydrates on gastrointestinal form and symptoms in irritable bowel syndrome patients
Acronym: CRAIGS
Short title: Carbohydrate reduction and impact on gastrointestinal system Chief Investigator: Prof Robin Spiller
Objectives:
The purpose of this study is to:
- Investigate the proportion of patients with Irritable Bowel Syndrome who report moderate or substantial improvement in their symptoms after 2 weeks of following a diet low in Fermentable Oligo-Di-Monosaccharides and Polyols (FODMAPs) compared to patients who are on their habitual diet.
- Determine the difference in colonic volume of IBS patients receiving immediate low FODMAP dietary intervention after 2 weeks compared to patients who are not on the diet (delayed dietary intervention).
- Investigate the changes in self-reported food intolerance that occurs before dietary intervention.
Trial Configuration:
2-arm, parallel group, randomised, controlled trial
Setting :
Research clinic within NIHR Biomedical Research Unit, Secondary care
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
TRIAL / STUDY OBJECTIVES AND PURPOSE
The trial aims to investigate the effect of a diet low in FODMAPs on colonic morphology as well as in improving symptoms of irritable bowel syndrome (IBS).
This mechanistic information, along with the clinical data, will allow planning of larger, multi-centre studies of the low FODMAP diet in similar patients.
HYPOTHESES
- Patients on a low FODMAP diet for 2 weeks will have a decreased fasting colonic volume measured by Magnetic Resonance Imaging (MRI) compared to participants who have not started the diet.
- Patients with IBS are more likely to report a clinically important improvement in symptoms following the low FODMAP diet (immediate intervention) compared to those on their habitual diet (delayed intervention).
PRIMARY OBJECTIVE • To compare the proportion of IBS patients reporting a clinically important improvement in symptoms following a low FODMAP diet for 2 weeks against IBS patients who are on their habitual diet.
SECONDARY OBJECTIVES
• Determine the difference in fasting colonic volume of IBS patients receiving low FODMAP dietary intervention after 2 weeks compared to those on habitual diet.
TRIAL DESIGN
This will be a pilot single-blind, randomised, controlled trial (RCT). Since some activity will take place on the University of Nottingham this will be a multi-centre study.
All participants will receive advice from a dietitian on the low FODMAP diet. They will be randomised to one of two parallel treatment arms:
- Low FODMAP dietary advice (immediate intervention)
- Habitual diet (control - delayed intervention )
Tipo de estudo
Intervencional
Inscrição (Real)
65
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Reino Unido, NG7 2UH
- Nottingham Digestive Diseases Centre
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Aged 18 and above
- Able to give informed consent
- Previous Diagnosis of IBS by medical practitioner
- Meeting ROME III criteria for IBS
- Investigations showing negative tissue transglutaminase (tTG) IgA antibodies
- Full blood count test does not indicate Anaemia
Exclusion Criteria:
Inclusion
- Aged 18 and above
- Able to give informed consent
- Previous Diagnosis of IBS by medical practitioner
- Meeting ROME III criteria for IBS
- Investigations showing negative tissue transglutaminase (tTG) IgA antibodies
- Full blood count test does not indicate Anaemia
Exclusion
- Children (<18 years)
History declared by the candidate of pre-existing gastrointestinal disorder, including but not limited to:
- Inflammatory Bowel Disease
- Coeliac Disease
- Pancreatitis
- Gallstone disease (biliary colic, cholecystitis)
- Diverticulitis
- Cancer of the gastrointestinal tract
- Reported history of previous resection of any part of the gastrointestinal tract other than appendix or gallbladder
- Intestinal stoma
- Limited understanding of English
- Pregnancy declared by the candidate
- Red flag symptoms such as rectal bleeding, family history of bowel or ovarian cancer, a change in bowel habit to looser and/or more frequent stools persisting for more than six weeks in a person aged over 60 years.
- Investigations showing positive tissue transglutaminase (tTG) IgA antibodies
- Anaemia confirmed by full blood count test
- Habitual use of opiate analgesics likely to alter bowel function e.g. morphine
- Use of antibiotics in the preceding four weeks other than for treatment of index infection.
- Any condition where the candidate is likely to require a course of antibiotics in the next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract infection, lower limb ulceration
- Inability to complete the symptom questionnaires e.g. cognitive dysfunction limiting memory and understanding
- Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g. chaotic lifestyle related to substance abuse
- Dietary practice not compatible with safe implementation of the trial diet e.g.veganism
- Medical reasons for pre-existing controlled diet that cannot be safely randomised e.g. end-stage kidney disease, diabetes
- Participants taking prebiotic/probiotic
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Immediate Intervention
Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
|
Both arms will receive the intervention but at different time points.
|
|
Comparador de Placebo: Delayed Intervention
Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
|
Both arms will receive the intervention but at different time points.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adequate symptom relief between cases and controls
Prazo: Assessed in cases on their last day of the intervention (2 weeks after dietary change). Assessed in controls before they began their intervention (between 1-2 weeks before dietary changes)
|
Adequate symptom relief assessed by questionnaire after intervention in cases and before intervention in cases
|
Assessed in cases on their last day of the intervention (2 weeks after dietary change). Assessed in controls before they began their intervention (between 1-2 weeks before dietary changes)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Changes in colonic volume between cases and controls from baseline
Prazo: Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
A change in colonic volume measured in milliliters (ml) from baseline and after intervention in cases.
This will compared with a change in colonic volume from baseline and before intervention in controls.
|
Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
|
Changes in fermentation between cases and controls
Prazo: Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
A change in breath hydrogen concentration measured in parts per million (ppm) from: baseline and after intervention (cases) ii) from baseline and before intervention (controls)
|
Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de janeiro de 2016
Conclusão Primária (Real)
1 de julho de 2017
Conclusão do estudo (Real)
1 de agosto de 2017
Datas de inscrição no estudo
Enviado pela primeira vez
18 de agosto de 2017
Enviado pela primeira vez que atendeu aos critérios de CQ
1 de novembro de 2018
Primeira postagem (Real)
2 de novembro de 2018
Atualizações de registro de estudo
Última Atualização Postada (Real)
2 de novembro de 2018
Última atualização enviada que atendeu aos critérios de controle de qualidade
1 de novembro de 2018
Última verificação
1 de novembro de 2018
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 15081
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .